Results

1–10 of 13 results for Stargardt

Oral Gildeuretinol Slows Disease Progression in Early Stargardt Disease: Updates From the TEASE-3 Study
Kenneth C Fan, MD, MBA
Annual Meeting Talks
2025
Stargardt Disease - Autofluorescence
Manish Nagpal, MD, FRCS (UK) ,FASRS
Retina Image Bank: Images of the Week
2026
Eighteen-Month Results From the Phase 1b-2 Study of Tinlarebant in Adolescent Subjects with Stargardt Disease
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2023
MCO-010 Optogenetic Therapy for Severe Vision Loss in Stargardt Disease: 6-Month Outcomes From the Phase 2 STARLIGHT Trial
Allen C Ho, MD FASRS
Annual Meeting Talks
2023
Oral Gildeuretinol Acetate 14 mg Capsules Stalled Stargardt Disease Progression: Updates in the TEASE-3 Study
Michael Gorin, MD, PhD
Annual Meeting Talks
2024
Qualitative Analysis of Imaging Features and Predictors of Visual Acuity in ABCA4- and PRPH2-Related Disease
Kenneth C Fan, MD, MBA
Annual Meeting Talks
2024
Safety, Tolerability, and Efficacy of Tinlarebant: 24-Month Primary Outcomes of the Phase 2 Study in Adolescent Patients With Stargardt Disease
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2024
B-FAF in Stargardt's Disease
Retina Image Bank: Images of the Week
2024
Fundus Flavimaculatus
Filip Kecer
Retina Image Bank: Images of the Week
2022
Stargardt Disease
Filip Kecer
Retina Image Bank: Images of the Week
2022